DSSG Group: Gynaecological

Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy.

recurrent or stage IVB cervical cancer

This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer.

Arm H (currently open) includes the drug regimens (pembrolizumab, bevacizumab, carboplatin, and Tisotumab vedotin), and will be triplet or quadruplet combination based on bevacizumab eligibility.

Platinum resistant Recurrent Ovarian Cancer (PROT)

Patients can have epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1-2 prior lines of systemic therapy, including at least 1 prior platinum-based therapy with ≥4 cycles in first line.

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival.

Stage III Epithelial Ovarian Cancer

The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm)

High-Risk Locally advanced cervical carcinoma

To compare the use of Chemoradiotherapy with or without Pembrolizumab for the treatment of High-risk Locally Advanced Cervical Cancer